Autologous haematopoietic stem cell transplantation (aHSCT) has been used to stop autoimmune processes in multiple sclerosis (MS), although the treatment is not effective for every person. Now, an improved version of the technique is showing astonishingly good results, with patients free of both the need for treatment and the risk of relapses for years on end — but the risk associated with the procedure is substantial.
The study, “Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial,” was published in the journal The Lancet.
FULL ARTICLE ON MS NEWS TODAY:
http://multiplesclerosisnewstoday.co...isks-are-high/
The study, “Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial,” was published in the journal The Lancet.
FULL ARTICLE ON MS NEWS TODAY:
http://multiplesclerosisnewstoday.co...isks-are-high/